Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
European urology(2023)
摘要
We show that talazoparib was associated at least with no change or improvements in health-related quality of life (HRQoL) and pain burden in men with metastatic castration-resistant prostate cancer and DNA damage response/homologous recombination repair gene alterations in the TALAPRO-1 study. These findings in patient-reported HRQoL and pain complement the antitumor activity and tolerability profile of talazoparib.
更多查看译文
关键词
BRCA1/2 status,Brief Pain Inventory,DNA damage response alteration,Metastatic castration-resistant prostate cancer,Patient-reported outcomes,Poly(ADP-ribose) polymerase inhibitor,TALAPRO-1 trial,Talazoparib
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络